NEWLY formed generic and OTC pharmaceuticals giant Arrotex Pharmaceuticals has announced the appointment of its new executive team to lead the integration, enablement and growth of the Arrow and Apotex merged entity.
Arrotex will be led by Dennis Bastas as Chairman and CEO, as announced earlier this month (PD 11 Jul).
The executive team includes Lisa Golden, named Chief Commercial Officer, Andrew Burgess appointed Chief Financial Officer and Sue Morgan in the role of Chief Legal Counsel.
Golden worked as Apotex Marketing Director, Asia Pacific for more than four years, before taking the role of Director of Business Development and Strategy, Mundipharma Australia in Oct 2017.
She brings an MBA and is a graduate of the Australian Institute Company Directors.
Burgess is a Chartered Accountant and has served alongside Bastas for more than 10 years, most recently as Arrow COO.
Prior to this, he played a pivotal role in the success of both Central Healthcare Services and Ascent Pharmaceuticals in the role of COO and CFO, respectively.
Morgan has worked as General Manager, Arrow Pharmaceuticals for nearly four years.
Prior to this, she worked as General Counsel and Company Secretary with Sigma for more than eight years.
Roger Millichamp, who successfully led Apotex Australia for the past 12 years, chose to use the opportunity to leave and pursue other options after a period supporting the transition.
The above article was sent to subscribers in Pharmacy Daily's issue from 24 Jul 19
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 24 Jul 19
